For the quarter ending 2025-09-30, RNA has $2,134,209K in assets. $247,944K in debts. $350,158K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 350,158 | 243,907 | ||
| Marketable securities | 1,525,678 | 939,237 | ||
| Prepaid and other current assets | 90,181 | 67,416 | ||
| Total current assets | 1,966,017 | 1,250,560 | ||
| Property and equipment, net | 21,504 | 20,535 | ||
| Restricted cash | 2,798 | 2,798 | ||
| Right-of-use assets | 52,848 | 4,227 | ||
| Other assets | 91,042 | 90,806 | ||
| Total assets | 2,134,209 | 1,368,926 | ||
| Accounts payable | 9,626 | 3,914 | ||
| Accrued expenses and other liabilities | 137,163 | 95,236 | ||
| Lease liabilities, current portion | 3,967 | 3,925 | ||
| Accrued compensation | - | 18,449 | ||
| Deferred revenue, current portion | 19,123 | 13,537 | ||
| Total current liabilities | 169,879 | 135,061 | ||
| Lease liabilities, net of current portion | 45,999 | 1,210 | ||
| Deferred revenue, net of current portion | 32,066 | 39,991 | ||
| Total liabilities | 247,944 | 176,262 | ||
| Common stock, 0.0001 par value authorized shares 400,000 issued and outstanding shares 146,771 and 119,893 at september30, 2025 and december31, 2024, respectively | 15 | 12 | ||
| Additional paid-in capital | 3,225,078 | 2,357,029 | ||
| Accumulated other comprehensive income | 1,768 | 1,777 | ||
| Accumulated deficit | -1,340,596 | -1,166,154 | ||
| Total stockholders equity | 1,886,265 | 1,192,664 | ||
| Total liabilities and stockholders equity | 2,134,209 | 1,368,926 | ||
Avidity Biosciences, Inc. (RNA)
Avidity Biosciences, Inc. (RNA)